Incidence of adverse effects Very common (>10% incidence) adverse effects include: * Dizziness secondary to orthostatic hypotension (17%) Common (1-10% incidence) adverse effects include: * Tachycardia (5-10%) * Hypomania (7%) * Paresthesia (5%) * Weight loss (2%) * Confusion (2%) * Dry mouth (2%) * Sexual function disorders (2%) * Hypertension (1–2 hours after ingestion) (2%) * Rash (2%) * Urinary retention (2%) Other (unknown incidence) adverse effects include: * Increased/decreased appetite * Blood dyscrasias * Chest pain * Diarrhea * Edema * Hallucinations * Hyperreflexia * Insomnia * Jaundice * Leg cramps * Myalgia * Palpitations * Sensation of cold * Suicidal ideation * Tremor Of note, there has not been found to be a correlation between sex and age below 65 regarding incidence of adverse effects.<unk>  is not associated with weight gain and has a low risk for hepatotoxicity compared to the hydrazine MAOIs. It is generally recommended that MAOIs be discontinued prior to anesthesia; however, this creates a risk of recurrent depression. In a retrospective observational cohort study, patients on<unk>  undergoing general anesthesia had a lower incidence of intraoperative hypotension, while there was no difference between patients not taking an MAOI regarding intraoperative incidence of bradycardia, tachycardia, or hypertension. The use of indirect sympathomimetic drugs or drugs affecting serotonin reuptake, such as meperidine or dextromethorphan poses a risk for hypertension and serotonin syndrome respectively; alternative agents are recommended. Other studies have come to similar conclusions. Pharmacokinetic interactions with anesthetics are unlikely, given that<unk>  is a high-affinity substrate for CYP2A6 and does not inhibit CYP enzymes at therapeutic concentrations.<unk>  abuse has been reported at doses ranging from 120 to 600 mg per day. It is thought that higher doses have more amphetamine-like effects and abuse is promoted by the fast onset and short half-life of<unk> . Cases of suicidal ideation and suicidal behaviours have been reported during<unk>  therapy or early after treatment discontinuation. Symptoms of<unk>  overdose are generally more intense manifestations of its usual effects.
Tranylcypromine
Patiromer
Dimethazan
Veristrat
Bretylium
Rauwolscine
Levomethamphetamine
Propylamphetamine